Cargando…

Chemotherapy-radiation interactions in human cervix carcinoma xenografts.

The combination of irradiation and four agents of clinical interest in the treatment of cervix carcinoma (bleomycin, etoposide, cisplatin and ifosfamide) have been investigated using two human cervix carcinoma xenografts in nude mice. As a model of clinical brachytherapy regimes, radiation was admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonkin, K. S., Kelland, L. R., Steel, G. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1988
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246868/
https://www.ncbi.nlm.nih.gov/pubmed/2465016
_version_ 1782150859192270848
author Tonkin, K. S.
Kelland, L. R.
Steel, G. G.
author_facet Tonkin, K. S.
Kelland, L. R.
Steel, G. G.
author_sort Tonkin, K. S.
collection PubMed
description The combination of irradiation and four agents of clinical interest in the treatment of cervix carcinoma (bleomycin, etoposide, cisplatin and ifosfamide) have been investigated using two human cervix carcinoma xenografts in nude mice. As a model of clinical brachytherapy regimes, radiation was administered at a continuous low dose rate of 5 cGy min-1 to a total dose of 9 or 12 Gy. No substantial enhancement in tumour growth delay over that observed for radiation alone was observed with bleomycin, etoposide or cisplatin. Ifosfamide, however, led to substantial additional growth delay, an effect which was lost when irradiation was administered at a higher dose rate of 70 cGy min-1. As dose-rates of around 5 cGy min-1 allow greater repair of radiation damage than at the higher dose-rate without significant cell cycling or repopulation, it is possible that ifosfamide may act as an inhibitor of repair processes in this model. It would be of interest to evaluate the role of ifosfamide and brachytherapy regimes in the clinical treatment of carcinoma of the cervix.
format Text
id pubmed-2246868
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22468682009-09-10 Chemotherapy-radiation interactions in human cervix carcinoma xenografts. Tonkin, K. S. Kelland, L. R. Steel, G. G. Br J Cancer Research Article The combination of irradiation and four agents of clinical interest in the treatment of cervix carcinoma (bleomycin, etoposide, cisplatin and ifosfamide) have been investigated using two human cervix carcinoma xenografts in nude mice. As a model of clinical brachytherapy regimes, radiation was administered at a continuous low dose rate of 5 cGy min-1 to a total dose of 9 or 12 Gy. No substantial enhancement in tumour growth delay over that observed for radiation alone was observed with bleomycin, etoposide or cisplatin. Ifosfamide, however, led to substantial additional growth delay, an effect which was lost when irradiation was administered at a higher dose rate of 70 cGy min-1. As dose-rates of around 5 cGy min-1 allow greater repair of radiation damage than at the higher dose-rate without significant cell cycling or repopulation, it is possible that ifosfamide may act as an inhibitor of repair processes in this model. It would be of interest to evaluate the role of ifosfamide and brachytherapy regimes in the clinical treatment of carcinoma of the cervix. Nature Publishing Group 1988-12 /pmc/articles/PMC2246868/ /pubmed/2465016 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Tonkin, K. S.
Kelland, L. R.
Steel, G. G.
Chemotherapy-radiation interactions in human cervix carcinoma xenografts.
title Chemotherapy-radiation interactions in human cervix carcinoma xenografts.
title_full Chemotherapy-radiation interactions in human cervix carcinoma xenografts.
title_fullStr Chemotherapy-radiation interactions in human cervix carcinoma xenografts.
title_full_unstemmed Chemotherapy-radiation interactions in human cervix carcinoma xenografts.
title_short Chemotherapy-radiation interactions in human cervix carcinoma xenografts.
title_sort chemotherapy-radiation interactions in human cervix carcinoma xenografts.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246868/
https://www.ncbi.nlm.nih.gov/pubmed/2465016
work_keys_str_mv AT tonkinks chemotherapyradiationinteractionsinhumancervixcarcinomaxenografts
AT kellandlr chemotherapyradiationinteractionsinhumancervixcarcinomaxenografts
AT steelgg chemotherapyradiationinteractionsinhumancervixcarcinomaxenografts